NervGen Pharma Corp. (NGEN)
NASDAQ: NGEN · Real-Time Price · USD
1.620
+0.020 (1.25%)
Jul 31, 2026, 4:00 PM EDT - Market closed

NervGen Pharma Financials Overview

Millions CAD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-26.58-25.08-25.18-17.78-23.03-12.81
Net Income
-41.84-44.12-24.25-22.38-20.72-12.73
Earnings Per Share
-0.63-0.61-0.36-0.38-0.39-0.32
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
16.5622.0717.2711.6622.4516.93
Total Debt
-0.010.110.20.28-
Net Cash (Debt)
16.5622.0617.1611.4622.1716.93
Net Cash Growth
15.08%28.55%49.72%-48.29%30.95%202.38%
Net Cash Per Share
0.220.300.250.190.420.43

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-23.58-19.5-16.84-11.3-17.78-8.27
Capital Expenditures
----0.01-0.02-0
Free Cash Flow
-23.58-19.5-16.84-11.3-17.81-8.27
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.